Carcinoid and neuroendocrine tumors: building on success

J Clin Oncol. 2015 Jun 1;33(16):1855-63. doi: 10.1200/JCO.2014.60.2532. Epub 2015 Apr 27.

Abstract

We have come a long way in our understanding and treatment of neuroendocrine tumors since the term "karzinoide" was coined in 1907. Neuroendocrine tumors are a group of biologically and clinically heterogeneous neoplasms that most commonly originate in the lungs, GI tract, and pancreas. The selection of initial and subsequent therapies requires careful consideration of both tumor and treatment characteristics. With recent advances, we now have more tools for the diagnosis and treatment of our patients. This comprehensive review article summarizes recent advances in the field of neuroendocrine tumors and places them into context for best management practices.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism
  • Carcinoid Tumor / drug therapy*
  • Carcinoid Tumor / genetics
  • Carcinoid Tumor / metabolism
  • Carcinoid Tumor / mortality
  • Carcinoid Tumor / pathology
  • Cell Differentiation
  • Chemoembolization, Therapeutic
  • Chemotherapy, Adjuvant
  • Humans
  • Neoplasm Staging
  • Neuroendocrine Tumors / drug therapy*
  • Neuroendocrine Tumors / genetics
  • Neuroendocrine Tumors / metabolism
  • Neuroendocrine Tumors / mortality
  • Neuroendocrine Tumors / pathology
  • Patient Selection
  • Precision Medicine
  • Predictive Value of Tests
  • Radiopharmaceuticals / therapeutic use
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Hormonal
  • Biomarkers, Tumor
  • Radiopharmaceuticals